Related Experiment Video

Updated: Aug 23, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

The Impact of Eribulin on Stathmin Dynamics and Paclitaxel Sensitivity in Ovarian Cancer Cells

Mana Azumi1, Mikihiro Yoshie1, Wataru Takano1

  • 1Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences.

Biological & Pharmaceutical Bulletin
|November 3, 2022
PubMed

Insights

Eribulin, a microtubule dynamics inhibitor, suppresses ovarian cancer cell proliferation by phosphorylating stathmin, a key protein. This action enhances chemotherapy efficacy, offering new therapeutic strategies for ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Eribulin is an established treatment for breast cancer and sarcoma.
  • Stathmin, a microtubule-destabilizing protein, influences eribulin's efficacy in certain cancers.
  • The role of eribulin in ovarian cancer remains incompletely understood.

Purpose of the Study:

  • To investigate the antitumor efficacy of eribulin in ovarian cancer.
  • To elucidate the involvement of stathmin in eribulin's activity against ovarian cancer cells.

Main Methods:

  • Xenograft models of ovarian cancer were utilized.
  • In vitro studies involved cultured ovarian cancer cell lines.
  • Stathmin phosphorylation, protein phosphatase 2A (PP2A) activity, and gene expression were analyzed.
  • Stathmin knockdown experiments were performed.

Main Results:

  • Eribulin treatment significantly reduced tumor weight in vivo.
  • Eribulin increased stathmin phosphorylation in both xenograft models and cell lines.
  • FTY720, a PP2A activator, inhibited eribulin-induced stathmin phosphorylation, and eribulin downregulated PP2A subunits.
  • Stathmin knockdown abolished eribulin's inhibitory effects on cell viability.
  • Eribulin enhanced paclitaxel's antiproliferative effects and decreased stathmin expression.

Conclusions:

  • Eribulin suppresses ovarian cancer cell proliferation, partly through regulating stathmin activity.
  • Eribulin-induced stathmin phosphorylation, potentially mediated by PP2A downregulation, is a key mechanism.
  • This study suggests a novel therapeutic approach for ovarian cancer by combining eribulin with other chemotherapies.
Keywords:
eribulinmicrotubuleovarian cancerprotein phosphatase 2Astathmin

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.6K
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

10.0K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K